Whalesbook
Toh hua kya hai, Lupin ko U.S. FDA se do important approvals mile hain. First, COPD ke liye Revefenacin Inhalation Solution ka 'tentative' approval mila hai. Aur dusra, Famotidine Injection USP ka final approval mil gaya. Ye dono drugs company ke portfolio ko strong banayenge. Revefenacin ke reference drug Yupelri ka market $260.7 million tak ka tha March 2026 tak. Aur Famotidine Injection ka annual market $8.7 million ka hai. Yeh injection Nagpur facility mein banega.
Company actually complex generics aur injectables ki taraf badh rahi hai, taaki oral generics ke crowded market se nikal kar zyada profit kama sake. COPD market bada hai, lagbhag $24.67 billion (2024) ka, aur 2032 tak yeh $35.15 billion ho sakta hai, matlab 4.9% ka CAGR.
Lekin bhai, stock girne ka reason kya hai? Sabse pehle toh pricing pressure. U.S. mein pharma sector ka growth slow hai, aur price hikes bhi pehle se kam honge (4.5-7.5% tak hi expected hain 2030 tak). Aur naya Inflation Reduction Act (IRA) bhi pressure bana raha hai. Dusra, Revefenacin ka approval 'tentative' hai. Iska matlab hai ki jab tak reference drug ke patents expire nahi ho jate, tab tak company isse market mein nahi laa sakti - matlab delay ho sakta hai. Teesra, Famotidine Injection ka market $8.7 million ka hai, jo bahut bada revenue nahi dega. Aur haan, Lupin ke Nagpur plant ko pehle bhi FDA observations mile the September 2025 mein, jisse compliance ko lekar sawal uthte hain. Competition bhi kam nahi hai - COPD mein Boehringer Ingelheim, GSK, Pfizer jaise players hain, aur Merck hai GI side par. Mylan (Viatris) bhi ek bada competitor hai.
Abhi stock thoda underperform kar raha hai aur investors ko chinta hai, lekin analysts ka view abhi bhi mostly positive hai. Kaafi log isse 'Moderate Buy' keh rahe hain aur average target price ₹2,460 ke aas paas de rahe hain. Matlab, future mein 9-11% tak ka upside dikh raha hai. Yeh optimism company ke complex generics aur injectables par focus karne ki strategy aur global reach ki wajah se hai.